New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
06:31 EDTENDPEndo Health downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital downgraded Endo Health given valuation and concerns regarding the future of the Opana ER franchise due to potential future generics. Price target lowered to $24 from $25.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
07:46 EDTENDPEndo valuation attractive, says Goldman
Subscribe for More Information
August 8, 2014
09:00 EDTENDPBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use